Seizures in a teenager as a manifestation of 22q11.2 deletion syndrome




22q11.2 deletion syndrome, DiGeorge syndrome, hypoparathyroidism, hypocalcemia, seizures


22q11.2 deletion syndrome (DiGeorge syndrome) is one of the most common chromosomal abnormalities, which is characterized by multiplicity and variability of damage to various organs and systems: cardiovascular, immune, nervous, endocrine, skeletal.

Purpose - to increase doctors' awareness regarding the diagnosis of 22q11.2 deletion syndrome in patients with seizure disorder based on a clinical case analysis.

Here we report a clinical case of DiGeorge syndrome (22q11.2 deletion syndrome) in a boy with seizures diagnosed at the age of 14 years by genetic testing because of suspected epileptic encephalopathy. Diagnosed hypofunction of the parathyroid gland and hypocalcemia are obviously the cause of seizures and required a change in treatment. Despite the presence of T- and B-lymphopenia, the boy did not have a frequent infectious syndrome. The absence of defining signs of the 22q11.2 deletion syndrome at an early age, namely the absence of data for a congenital heart defect, pronounced facial dysmorphias, frequent infections, did not give an opportunity to suspect this syndrome at an early age.

Taking into account the prevalence, multiplicity and variability of the lesion and the varying degree of severity of clinical manifestations in 22q11.2 deletion syndrome, patients with this syndrome can be found in the practice of every doctor. With seizures in combination with developmental disorders, it is necessary to rule out 22q11.2 deletion syndrome at any age. Wider awareness of the dysmorphic and clinical manifestations of this syndrome will allow better diagnosis of this disease, which requires a multidisciplinary approach to management.

The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies.

No conflict of interest was declared by the authors.


Andrade DM, Krings T, Chow EW, Kiehl TR, Bassett AS. (2013). Hippocampal malrotation is associated with chromosome 22q11.2 microdeletion. Can J Neurol Sci. 40: 652-656.; PMid:23968937 PMCid:PMC4459860

Bassett AS, McDonald-McGinn DM, Devriendt K et al. (2011). Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr. 159: 332-339.; PMid:21570089 PMCid:PMC3197829

Boot E, Óskarsdóttir S, Loo JCY et al. (2023). Updated clinical practice recommendations for managing adults with 22q11.2 deletion syndrome. Genet Med. 25 (3): 100344.; PMid:36729052

Boyarchuk O, Kinash M, Hariyan T, Bakalyuk T. (2019). Evaluation of knowledge about primary immunodeficiencies among postgraduate medical students. Archives of the Balkan Medical Union. 54 (1): 11-19.

Boyarchuk O, Lewandowicz-Uszyńska A, Kinash M, Haliyash N, Sahal I, Kovalchuk T. (2018). Physicians' awareness concerning primary immunodeficiencies in the Ternopil Region of Ukraine. Pediatria Polska. 93 (3): 221-228.

Boyarchuk O, Volyanska L, Dmytrash L. (2018). Clinical variability of chromosome 22q11.2 deletion syndrome. Cent Eur J Immunol. 42 (4): 412-417.; PMid:29472823 PMCid:PMC5820982

Boyarchuk O, Volyanska L, Kosovska T, Lewandowicz-Uszynska A, Kinash M. (2018). Awareness of primary immunodeficiency diseases among medical students. Georgian Med News. 285: 124-130.

Butcher NJ, Chow EW, Costain G, Karas D, Ho A, Bassett AS. (2012). Functional outcomes of adults with 22q11.2 deletion syndrome. Genet Med. 14 (10): 836-843.; PMid:22744446 PMCid:PMC3465579

Campbell LE, Swaab L, Freeman EE et al. (2022). The Importance of Understanding Individual Differences of Emotion Regulation Abilities in 22q11.2 Deletion Syndrome. J Autism Dev Disord. 52 (7): 3076-3087.; PMid:34251567

Cheung EN, George SR, Andrade DM, Chow EW, Silversides CK, Bassett AS. (2014). Neonatal hypocalcemia, neonatal seizures, and intellectual disability in 22q11.2 deletion syndrome. Genet Med. 16: 40-44.; PMid:23765047 PMCid:PMC4459858

Cirillo A, Lioncino M, Maratea A et al. (2022). Clinical Manifestations of 22q11.2 Deletion Syndrome. Heart Fail Clin. 18 (1): 155-164.; PMid:34776076

Evers LJ, van Amelsvoort TA, Candel MJ, Boer H, Engelen JJ, Curfs LM. (2014). Psychopathology in adults with 22q11 deletion syndrome and moderate and severe intellectual disability. J Intellect Disabil Res. 58 (10): 915-25.; PMid:24528781

Fiksinski AM, Breetvelt EJ, Lee YJ et al. (2019). Neurocognition and adaptive functioning in a genetic high risk model of schizophrenia. Psychol Med. 49 (6): 1047-1054.; PMid:30064532

Fung WL, Butcher NJ, Costain G et al. (2015). Practical guidelines for managing adults with 22q11.2 deletion syndrome. Genet Med. 17 (8): 599-609.; PMid:25569435 PMCid:PMC4526275

Khlunovska LY, Maslianko MM. (2020). A clinical case of di georgi syndrome in twins. Neonatology, Surgery and Perinatal Medicine. 10; 1 (35): 79-84.

Kobrynski LJ, Sullivan KE. (2007). Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet. 370: 1443-1452.; PMid:17950858

Lackey AE, Muzio MR. (2023, Jan). DiGeorge Syndrome. Treasure Island (FL). URL:

McDonald-McGinn DM, Sullivan KE, Marino B et al. (2015). 22q11.2 deletion syndrome. Nat Rev Dis Primers. 1: 15071.; PMid:27189754 PMCid:PMC4900471

Patel K, Akhter J, Kobrynski L et al. (2012). International DiGeorge Syndrome Immunodeficiency Consortium. Immunoglobulin deficiencies: the B-lymphocyte side of DiGeorge Syndrome. J Pediatr. 161: 950-953.; PMid:22809661

Shveikina VB, Martyniuk VY. (2022). To the issue of diagnosis of neuropsychological development of newborns and young children. Modern pediatrics. Ukraine. 8 (128): 45-67.

Sullivan KE. (2002). Immunologic issues in VCFS/chromosome 22q11.2 deletion syndrome. Prog Pediatr Cardiol. 15: 103-108.

Tangye SG, Al-Herz W, Bousfiha A et al. (2022). Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 42 (7): 1473-1507.; PMid:35748970 PMCid:PMC9244088